Messenger Ribonucleic Acid (mRNA) and Next-Generation Vaccine Platforms Market Report 2026

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has grown rapidly in recent years. It will grow from $39.69 billion in 2025 to $45.88 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to COVID-19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size is expected to see rapid growth in the next few years. It will grow to $82.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growth of personalized cancer vaccines, expansion of infectious disease pipelines, faster platform based approvals, increased biotech funding, broader therapeutic vaccine use. Major trends in the forecast period include self amplifying mrna platforms, lipid nanoparticle delivery optimization, modular vaccine platform design, rapid pathogen target adaptation, next generation adjuvant systems.

The increasing demand for personalized medicine is anticipated to drive the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in the coming years. Personalized medicine refers to a medical approach in which disease prevention and treatment strategies are tailored based on an individual’s genetic profile, molecular characteristics, and specific health conditions. The rising demand for personalized medicine is driven by the increasing prevalence of complex and chronic diseases, which require targeted and patient-specific therapeutic solutions to improve treatment efficacy and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms support personalized medicine by enabling rapid, flexible, and highly specific vaccine and therapeutic designs that can be customized to individual genetic and disease profiles, supporting precision-based healthcare delivery. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

Companies operating in the mRNA and next-generation vaccine platforms market are focusing on developing next-generation mRNA-based COVID-19 vaccines to enhance immune durability, broaden variant coverage, and improve overall vaccine performance. Next-generation mRNA-based COVID-19 vaccines leverage improved mRNA engineering and delivery technologies to provide broader and more durable protection against existing and emerging SARS-CoV-2 variants and enhance safety, stability, and storage convenience while allowing rapid adaptation to viral evolution. For example, in June 2025, Moderna Inc., a US-based biotechnology company, introduced mNEXSPIKE, its next-generation COVID-19 vaccine designed to improve protection against circulating and emerging SARS-CoV-2 variants. The vaccine incorporates an updated spike protein antigen that more closely matches recent variants and aims to deliver enhanced immune durability and effectiveness, supporting ongoing COVID-19 prevention efforts and future booster strategies.

In July 2024, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, partnered with CureVac N.V. to advance next-generation mRNA vaccines and accelerate development. The partnership aims to fortify GlaxoSmithKline's vaccine pipeline by gaining strategic control over next-generation mRNA programs and expediting their development and commercialization. CureVac N.V. is a Germany-based biotechnology company specializing in next-generation messenger ribonucleic acid-based Covid and flu vaccines.

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Tariffs on bioprocess equipment, lipid materials, specialized enzymes, and cold chain components are influencing the mrna and next generation vaccine platforms market by increasing production and scale up costs. Platform manufacturing and delivery system segments are most affected where imported reagents and processing systems are widely used, especially in north america and europe. Higher import costs can raise vaccine development and commercialization budgets. However, tariffs are also encouraging local sourcing of raw materials and regional biomanufacturing capacity expansion. This supports domestic platform developers and regional vaccine supply chains.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market research report is one of a series of new reports that provides messenger ribonucleic acid (mrna) and next-generation vaccine platforms market statistics, including messenger ribonucleic acid (mrna) and next-generation vaccine platforms industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) and next-generation vaccine platforms market share, detailed messenger ribonucleic acid (mrna) and next-generation vaccine platforms market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms industry. This messenger ribonucleic acid (mrna) and next-generation vaccine platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms denote advanced vaccine technologies that utilize genetic instructions, including mRNA, DNA, or viral vectors, to activate the body’s immune system to produce protective proteins and establish immunity against diseases. These platforms facilitate faster vaccine development, high adaptability to emerging pathogens, scalable production, and enhanced immune responses compared to conventional vaccine methods.

The primary vaccine types of messenger ribonucleic acid (mRNA) and next-generation vaccine platforms include messenger ribonucleic acid vaccines, deoxyribonucleic acid (DNA) vaccines, viral vector vaccines, protein subunit vaccines, peptide vaccines, and other vaccine types. Messenger ribonucleic acid (mRNA) vaccines utilize synthetic mRNA sequences to instruct cells to produce specific antigens, thereby initiating an immune response against a target pathogen or disease. These platforms employ technologies including lipid nanoparticle (LNP) delivery, self-amplifying mRNA (saRNA), circular mRNA (circRNA), replicon or non-replicating platforms, and viral vector technologies. They are applied for disease indications including infectious diseases, oncology, rare diseases, and other medical conditions, and end users include pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, and hospitals and clinics.

The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market includes sales of messenger ribonucleic acid vaccines, lipid nanoparticle delivery systems, viral vector vaccines, protein subunit vaccines, recombinant antigen vaccines, next-generation adjuvants, synthetic ribonucleic acid constructs, stabilized messenger ribonucleic acid formulations, immune response modulators, and nucleic acid-based vaccine platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.